Braskem's 3-Year Slide: From Cheap Commodity Stock to Creditor Protection

Braskem's rating path turned a cyclical problem into a restructuring case

Braskem crossed the line in June. What once looked like a cyclical squeeze in chemicals became a protection from creditors story, and that changes what the equity is now. This is no longer a simple buy-the-dip petrochemical name; it is a restructuring claim, and timing matters because each week brings investors closer to a capital-structure outcome rather than a clean cyclical restart.

The rating trail makes that clear. After management hired financial advisors, agencies moved Braskem into distressed territory, with S&P at CCC- and Fitch at CCC+. Then, after Braskem received protection from creditors, the ratings moved further down the scale, with S&P at D and Fitch at C. For a Main Street investor, that is the key signal: a normal weak cycle does not get marked like a default case unless the balance sheet has very little room left.

Bulls still need to do more work

Bulls can still argue that the operating business may be salvageable once the legal process settles. Bears have the cleaner near-term argument: once a company is in creditor protection, common shareholders are last in line. In a commodity-chemical business, where product differentiation is limited and spreads drive performance, the first question is no longer brand loyalty. It is who gets paid first.

Why the old buy-the-dip story no longer holds

The old Braskem story broke when credit markets decided the balance sheet, not the product cycle, was the main risk.

The downgrade trail changed the setup

Braskem's rating path says the simple cyclical-restart check stopped passing. When management hired financial advisors, agencies treated that as evidence that restructuring risk was no longer theoretical, with S&P downgrading to CCC- and Fitch cutting to CCC+ at the same time. After Braskem received court protection from creditors, the downgrade trail moved into default-like territory, with S&P moving to D and Fitch to C. That is not what a normal cyclical dip looks like; it is what the market signals when a company has little room left to wait out a weak patch.

Claims hierarchy matters more than product differentiation

In a differentiated specialty-materials business, strong brand loyalty or better product quality can buy time. In commodity chemicals, the product lineup matters less because buyers can often switch when spreads weaken. What matters more is cost position, operating discipline, and balance-sheet stamina. If a plant is on the wrong side of the cost curve, running it can still burn cash. And once debt-service and refinancing pressure rise, operating effort alone does not solve the problem.

That is why the claims hierarchy matters so much here. Asset value can still support creditors, secured and unsecured lenders, and possibly new financing. But asset value sitting in the ground or inside a plant does not help common shareholders on the original timeline. Equity only wins if the recap leaves room for upside after every senior claim is accounted for.

Why I'm downgrading Braskem

I am downgrading Braskem and moving away from the stock until the story changes from restructuring process to recoverable-business proof. The barrier is straightforward: once a company is in a default-like creditor protection process, the old buy-the-dip shortcut no longer works. The key question is whether old equity keeps any real claim on the upside, or whether this remains a debt haircut and pie-slicing exercise for some time.

I would not say there is no upside. There may be. But the setup is no longer a normal chemical-cycle trade; it is a claims hierarchy trade, and in that kind of setup, patience usually matters more than optimism.

What bulls have to prove

Bulls can still make the case, but they need to support it with concrete developments over the next few months, not with hope. The central question is whether Braskem can move from survival mode to a plan that credibly changes creditor outcomes.

Watch for:

• Operating stabilization

  Signs that the core business is steadying enough to support a recap plan. In chemicals, that means plants running at meaningful rates, customers staying on the books, and cash generation improving from distress levels. If the business still looks like it is running through capital, the equity case stays weak.

• A recap that leaves room for old shares

  Even if creditors are protected, equity can still come out thin or worthless in the near term. The bull case needs a restructuring outcome that does more than keep the firm going; it also has to leave some upside for old shares.

What would change my view

I would revisit the stock if two things happen together: the business stops looking like a distress case, and the restructuring path starts producing a cleaner ownership outcome. Until then, a wait-and-see stance makes more sense.

That stance may mean missing a fast recovery. But in a restructuring, acting too early can feel cheap and turn out to be expensive.